Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966992 | 0.86 | DDB1 (0.33) | KMT2AMEN1SMN1; SMN2PARP1ALDH1A1 | |
| SCHEMBL3074348 | 0.82 | CYP2D6 (0.38) | KMT2AMEN1SMN1; SMN2P2RX7BRPF1 | |
| SCHEMBL3074344 | 0.82 | CYP2D6 (0.38) | KMT2AMEN1SMN1; SMN2P2RX7BRPF1 | |
| SCHEMBL3074342 | 0.82 | CYP2D6 (0.38) | KMT2AMEN1SMN1; SMN2P2RX7BRPF1 | |
| SCHEMBL4185620 | 0.80 | KMT2A (0.43) | KMT2AMEN1BRPF1CREBBPALDH1A1 | |
| SCHEMBL4185613 | 0.80 | KMT2A (0.43) | KMT2AMEN1BRPF1CREBBPALDH1A1 | |
| SCHEMBL4185609 | 0.80 | KMT2A (0.43) | KMT2AMEN1BRPF1CREBBPALDH1A1 | |
| SCHEMBL4179958 | 0.78 | — | — | |
| SCHEMBL3088031 | 0.78 | MEN1 (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1PTGS2 | |
| SCHEMBL3088036 | 0.78 | MEN1 (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0681568-B1 | PROCESS FOR PREPARATION OF TAXANE DERIVATIVES AND BETA-LACTAM INTERMEDIATES THEREFOR | UNIV NEW YORK STATE RES FOUND (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-0690856-B1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | UNIV NEW YORK STATE RES FOUND (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020045771-A1 | Family of canadensol taxanes, the semi-synthetic preparation and therapeutic use thereof | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2002-04-18 | — | — | US | disclosed |
| EP-0809627-B1 | NOVEL BORNEOL DERIVATIVES, METHODS OF MANUFACTURING THEM, AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 2001-09-12 | — | — | EP | disclosed |
| US-6218553-B1 | METALLIZATION BY REACTING A BACCATIN III DERIVATIVE WITH A METAL ALKYLDISILAZIDE | THE STATE UNIVERSITY OF NEW YORK AT STONY BROOK | 2001-04-17 | — | — | US | disclosed |
| US-6187916-B1 | Process for the preparation of taxane derivatives and β-lactam intermediates therefor | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2001-02-13 | — | — | US | disclosed |
| US-6025507-A | Borneol derivatives, methods of manufacturing them, and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | disclosed |
| US-5965609-A | Borneol esters, process for their production, and their pharmaceutical use | SCHERING AG (DE) | 1999-10-12 | — | — | US | disclosed |
| EP-0817769-B1 | BORNEOL ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 1999-05-26 | — | — | EP | disclosed |
| EP-0758316-B1 | BORNEOL DERIVATIVES AFFECTING TUBULIN POLYMERIZATION AND DEPOLYMERIZATION | SCHERING AG (DE) | 1998-11-18 | — | — | EP | disclosed |
| WO-1996032376-A1 | NOVEL BORNEOL ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-10-17 | — | — | WO | disclosed |
| WO-1996025392-A1 | NOVEL BORNEOL DERIVATIVES, METHODS OF MANUFACTURING THEM, AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-08-22 | — | — | WO | disclosed |
| EP-0690856-A4 | — | UNIV NEW YORK (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0690856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5475011-A | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995030650-A1 | BORNEOL DERIVATIVES AFFECTING TUBULIN POLYMERIZATION AND DEPOLYMERIZATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-11-16 | — | — | WO | disclosed |
| EP-0681568-A1 | PROCESS FOR PREPARATION OF TAXANE DERIVATIVES AND $g(b)-LACTAM INTERMEDIATES THEREFOR | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994022856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994018164-A1 | PROCESS FOR PREPARATION OF TAXANE DERIVATIVES AND β-LACTAM INTERMEDIATES THEREFOR | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5294737-A | Hydrolysis, cyclization, condensation | THE RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045771-A1 | Family of canadensol taxanes, the semi-synthetic preparation and therapeutic use thereof | MT-ATP8, MT-ATP6, CANX | KMT2A 4020/4885MEN1 3318/4885SMN1; SMN2 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.